Skip to main
PTCT

PTC Therapeutics (PTCT) Stock Forecast & Price Target

PTC Therapeutics (PTCT) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 10%

Bulls say

PTC Therapeutics is a company on the rise, with the recent launch of Sephience and positive results for votoplam driving market expectations for high sales and future potential. With an expanding international presence and promising pipeline, PTCT's valuation may not yet reflect the full potential of its assets, making it an attractive investment opportunity. However, potential regulatory challenges and the success of its products will heavily influence the stock's performance moving forward.

Bears say

PTC Therapeutics is facing multiple commercial, regulatory, and developmental risks that could impact its financial performance and stock valuation. The market may be underestimating its prospects for Sephience and the potential for Kuvan-to-Sephience switching, which could drive higher peak sales. Furthermore, PTC's current valuation appears to be implying lower peak sales for Sephience compared to the analyst's estimate of $2.4B. These risks indicate a negative outlook for the stock, as uncertainties surrounding revenue growth and regulatory hurdles may impact the company's ability to meet its financial targets and hinder stock performance.

PTC Therapeutics (PTCT) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of PTC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PTC Therapeutics (PTCT) Forecast

Analysts have given PTC Therapeutics (PTCT) a Buy based on their latest research and market trends.

According to 10 analysts, PTC Therapeutics (PTCT) has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PTC Therapeutics (PTCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.